Top

Published in:

01-12-2012 | Original Paper

Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia

Authors: Umran Kucukgoz Gulec, Semra Paydas, Ahmet Baris Guzel, Selim Buyukkurt, Gulsah Seydaoglu, Mehmet Ali Vardar

Published in: Medical Oncology | Issue 4/2012

Abstract

The aim of this study was to investigate the diagnostic role of the CA 125, ferritin, beta-2 microglobulin (β2 M), and lactic dehydrogenase (LDH) levels in serum and peritoneal fluid (PF) in patients with ovarian neoplasms. Using cross-sectional study design; serum and PF CA 125, ferritin, β2 M, and LDH levels were analyzed in 40 patients with benign ovarian neoplasms (Group 1) and 59 patients with malignant ovarian neoplasms (Group 2) which were evaluated surgically. Serum and PF levels of these markers compared between the groups. Diagnostic role of these markers were determined with receiver operating curve (ROC) analysis. Serum and PF CA 125, ferritin, β2 M, and LDH levels were statistically significant higher in patients with ovarian cancers as compared with benign neoplasms. Among these biomarkers, PF β2 M levels had highest sensitivity and specificity, 76.3 and 85%, respectively with the cut-off value: 2.3 mg/l. This study results indicates that especially PF β2 M and ferritin levels may be valuable for diagnosis of malignant ascites in patients with ovarian neoplasms.

Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29.PubMedCrossRef

Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011;2011:475983.PubMedCrossRef

Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384–9.PubMedCrossRef

Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267–77.PubMedCrossRef

Molina R, Filella X, Jo J, Ballesta AM. CA 125 in biological fluids. Int J Biol Markers. 1998;13:224–30.PubMed

Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ, Huebers HA. Plasma ferritin determination as a diagnostic tool. West J Med. 1986;145(5):657.PubMed

Schneider D, Halperin R, Langer R, et al. Peritoneal fluid lactate dehydrogenase in ovarian cancer. Gynecol Oncol. 1997;66:399–404.PubMedCrossRef

Yuce K, Baykal C, Genc C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynecol Oncol. 2001;22(3):228–32.

Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3:952–61.PubMedCrossRef

10.

Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res. 1997;27:95–102.PubMedCrossRef

11.

Cabrera T, López-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother. 2003;52(1):1–9.PubMed

12.

Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol. 2000;77:254–7.PubMedCrossRef

13.

Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264–5.PubMedCrossRef

14.

Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer. 2002;95(9):1886–93.PubMedCrossRef

15.

Tuzun Y, Celik Y, Bayan K, Yilmaz S, Dursun M, Canoruc F. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt? J Int Med Res. 2009;37(1):79–86.PubMed

16.

Halperin R, Hadas E, Bukovsky I, Schneider D. Peritoneal fluid analysis in the differentiation of ovarian cancer and benign ovarian tumor. Eur J Gynaecol Oncol. 1999;20(1):40–4.PubMed

17.

Yinnon A, Konijn AM, Link G, Moreb J, Hershko C. Diagnostic value of ferritin in malignant pleural and peritoneal effusions. Cancer. 1988;62(12):2564–8.PubMedCrossRef

18.

Tripathi PK, Chatterjee SK. Elevated expression of ferritin H-chain mRNA in metastatic ovarian tumor. Cancer Invest. 1996;14(6):518–26.PubMedCrossRef

19.

Pinto V, Marinaccio M, Garofalo S, Vittoria Larocca AM, Geusa S, Lanzilotti G, et al. Preoperative evaluation of ferritinemia in primary epithelial ovarian cancer. Tumori. 1997;83(6):927–9.PubMed

20.

Paydas S, Sargin O, Ozbek S, Gürbüz E. Ferritin levels in malignant effusions: a useful marker?. Eur J Cancer. 1990;26(8):919.PubMed

21.

Demirkazik A, Dinçol D, Hastürk S, Arican A, Karaoguz H, Cay F, Içli F. Diagnostic value of ferritin in the differential diagnosis of malignant effusions. Cancer Biochem Biophys. 1998;16(3):243–51.PubMed

22.

Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer. 1983;32(5):547–54.PubMedCrossRef

23.

Rolland P, Deen S, Scott I, Durrant L, Spendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res. 2007;13(12):3591–6.PubMedCrossRef

Title: Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia
Authors: Umran Kucukgoz Gulec
Semra Paydas
Ahmet Baris Guzel
Selim Buyukkurt
Gulsah Seydaoglu
Mehmet Ali Vardar
Publication date: 01-12-2012
Publisher: Springer US
Published in: Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-012-0165-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Coexpression of Bcl-2 with epithelial–mesenchymal transition regulators is a prognostic indicator in hepatocellular carcinoma

Increased expression of matrix metalloproteinase-13 in glioma is associated with poor overall survival of patients

The -938A/A genotype of BCL2 gene is associated with esophageal cancer

Rare pulmonary primitive neuroectodermal tumor metastasizing to the right atrium: a case report

Adjuvant chemoradiotherapy (CRT) for high-risk gastric cancer (GC) patients: single-center experience using infusional 5-fluorouracil (5FU) and radiotherapy (RT)

MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page